SCHEMBL873664

SCHEMBL873664

O=[C]C1(O)CC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4041370 0.86
SCHEMBL874397 0.86
SCHEMBL514286 0.83
SCHEMBL10971533 0.69
SCHEMBL10973183 0.68
SCHEMBL130928 0.61
SCHEMBL7671122 0.61
SCHEMBL1652805 0.58
SCHEMBL18613719 0.58
SCHEMBL11773472 0.57

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140309192-A1 MODULATORS OF THE G PROTEIN-COUPLED MAS RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO ARENA PHARMACEUTICALS, INC, 2014-10-16 US claimed
EP-2776407-A1 MODULATORS OF THE G PROTEIN-COUPLED MAS RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO Arena Pharmaceuticals, Inc. (US) 2014-09-17 EP claimed
EP-2643000-A2 THERAPEUTIC PIPERAZINES Dart Neuroscience (Cayman) Ltd (KY) 2013-10-02 EP claimed
WO-2013070657-A1 MODULATORS OF THE G PROTEIN-COUPLED MAS RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO ARENA PHARMACEUTICALS, INC. (US) 2013-05-16 WO claimed
EP-1846408-B1 5-MEMBERED ANNELATED HETEROCYCLIC PYRIMIDINES AS KINASE INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2013-03-20 EP claimed
WO-2012040258-A2 THERAPEUTIC PIPERAZINES HELICON THERAPEUTICS, INC. (US) 2012-03-29 WO claimed
US-20110263639-A1 Aryl-substituted bridged or fused diamines as modulators of leukotriene A4 hydrolase Janseen Pharmaceutical NV 2011-10-27 US claimed
US-20110257153-A1 Aryl-substituted bridged or fused diamines as modulators of leukotriene A4 hydrolase JANSSEN PHARMACEUTICAL NV 2011-10-20 US claimed
US-7947694-B2 Substituted pyrazolo[3,4-D]pyrimidines as cell cycle kinase inhibitors JANSSEN PHARMACEUTICA NV (BE) 2011-05-24 US claimed
US-7947695-B2 Inhibitors of cell cycle kinases such as cyclin dependent kinase CDK4 and/or the Aurora kinases; use in combination with an anticancer agent JANSSEN PHARMACEUTICA NV (BE) 2011-05-24 US claimed
EP-1844048-B1 PYRAZOLOPYRIMIDINES AS CELL CYCLE KINASE INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2010-05-26 EP claimed
WO-2009058347-A1 ARYL-SUBSTITUTED BRIDGED OR FUSED DIAMINES AS MODULATORS OF LEUKOTRIENE A4 HYDROLASE JANSSEN PHARMACEUTICA N.V. (BE) 2009-05-07 WO claimed
US-20090111794-A1 Aryl-substituted bridged or fused diamines as modulators of leukotriene A4 hydrolase JANSSEN PHARMACEUTICA N.V. (BE) 2009-04-30 US claimed
JP-2008526920-A 2008-07-24 JP claimed
US-20080070914-A1 Inhibitors of cell cycle kinases such as cyclin dependent kinase CDK4 and/or the Aurora kinases; use in combination with an anticancer agent JANSSEN-CILAG (FR) 2008-03-20 US claimed
US-20080039477-A1 Pyrazolopyrimidines as Cell Cycle Kinase Inhibitors JANSSEN PHARMACEUTICA N.V. (BE) 2008-02-14 US claimed
EP-1846408-A1 5-MEMBERED ANNELATED HETEROCYCLIC PYRIMIDINES AS KINASE INHIBITORS JANSSEN PHARMACEUTICA N.V. (BE) 2007-10-24 EP claimed
EP-1844048-A1 PYRAZOLOPYRIMIDINES AS CELL CYCLE KINASE INHIBITORS JANSSEN PHARMACEUTICA N.V. (BE) 2007-10-17 EP claimed
WO-2006074985-A1 5-MEMBERED ANNELATED HETEROCYCLIC PYRIMIDINES AS KINASE INHIBITORS JANSSEN PHARMACEUTICA N.V. (BE) 2006-07-20 WO claimed
WO-2006074984-A1 PYRAZOLOPYRIMIDINES AS CELL CYCLE KINASE INHIBITORS JANSSEN PHARMACEUTICA N.V. (BE) 2006-07-20 WO claimed